At the Society of Urologic Oncology Annual Meeting, Sumanta K. Pal, MD, City of Hope, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, break down the role of the microbiome and response in patients with kidney cancer. Together, they address ways to mediate the microbiome, the role of transplantation, and potential for immunotherapy in bladder cancer. ...
Renal Cell Carcinoma
Advertisement
Latest News
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
The NODESAFE model can aid in clinical decision-making and may spur consideration for adjuvant therapy in patients with RCC.
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
